/PRNewswire/ Amid repeated failures of drug trials for Alzheimer s disease, a small pilot study using a precision medicine approach has reported the first.
Trial First to Show Improvements in Alzheimer s Patients
News provided by
Share this article
Share this article
BURLINGAME, Calif., May 13, 2021 /PRNewswire/ Pharmaceutical trials for Alzheimer s have failed repeatedly, but a new study, using a fundamentally different approach, has provided the first success: using precision medicine to identify and target the drivers of Alzheimer s or pre-Alzheimer s in each patient, a team of physicians and researchers has posted exciting, positive results in medRxiv, the Yale-backed site for health sciences.
(PRNewsfoto/Apollo Health)
(PRNewsfoto/Apollo Health)
Until now, therapeutic development for Alzheimer s disease has been almost uniformly unsuccessful, with over 400 failed clinical trials. The few successes (e.g., memantine) have not offered sustained improvement. For example, the recent claim of a positive trial for the drug candidate donanemab did not show cognitive improvement, nor even stabilization of dementia, but merely red